Skip to main content

6 Result(s)

within G Ossenkoppele Remove this filter

and

  1. Article

    Open Access

    In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL

    S Laukkanen, T Grönroos, P Pölönen, H Kuusanmäki, J Mehtonen… in Blood Cancer Journal (2017)

    Download PDF (590 KB) View Article

  2. No Access

    Article

    Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

    The European Treatment and Outcome Study (EUTOS) population-based registry includes data of all adult patients newly diagnosed with Philadelphia chromosome-positive and/or BCR-ABL1+ chronic myeloid leukemia (C...

    V S Hoffmann, M Baccarani, J Hasford, F Castagnetti, F Di Raimondo, L F Casado… in Leukemia (2017)

  3. No Access

    Article

    Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

    Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with CN-AML in CR1, for whom mutat...

    J Versluis, F E M in ‘t Hout, R Devillier, W L J van Putten, M G Manz… in Leukemia (2017)

  4. Article

    Open Access

    Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

    The Evaluating Nilotinib Efficacy and Safety in Clinical Trials as First-Line Treatment (ENEST1st) study included 1089 patients with newly diagnosed chronic myeloid leukemia in chronic phase. The rate of deep ...

    A Hochhaus, G Rosti, N C P Cross, J L Steegmann, P le Coutre, G Ossenkoppele… in Leukemia (2016)

    Download PDF (398 KB) View Article

  5. No Access

    Article

    Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

    In patients with chronic myeloid leukemia (CML), first-line imatinib treatment leads to 8-year overall survival (OS) probabilities above 80%. Many patients die of reasons unrelated to CML. This work tackled th...

    M Pfirrmann, M Baccarani, S Saussele, J Guilhot, F Cervantes, G Ossenkoppele… in Leukemia (2016)

  6. No Access

    Article

    Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years

    The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate, especially in patients at higher risk of non...

    J J Cornelissen, J Versluis, J R Passweg, W L J van Putten, M G Manz… in Leukemia (2015)